nuclear pore complex interacting protein family, member B13Genealiases: []
Q-omics provides the consensus-scored NPIPB13 profile across patient tissues and cancer cell-line models. NPIPB13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NPIPB13 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, NPIPB13 RNA expression shows 11,605 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight MESO, STAD, and READ as cancer lineages where NPIPB13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB13 survival associations across molecular data types. NPIPB13 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB13 RNA expression–survival associations across cancer types. High NPIPB13 expression shows unfavorable associations in MESO, KIRC, STAD and UVM, but favorable associations in UCEC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for NPIPB13 RNA expression.
This table summarizes NPIPB13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB13 shows higher tumor expression in STAD, KIRC, KIRP, COAD, CHOL and KICH. The STAD box plot shows higher NPIPB13 RNA expression in tumor versus normal tissue (log2 FC = +0.370, t-test p < 0.001).
This table shows molecular features associated with NPIPB13 in patient tissues and cancer cell lines. In patient samples, NPIPB13 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPB13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
